Dr Chris Mason appointed Senior Editor of Regenerative Medicine

Jun 23 2008

The journal Regenerative Medicine has announced the promotion of Dr Chris Mason to Senior Editor. Dr Mason succeeds Dr Stephen Minger who has steered the journal since its launch in January 2006.

Dr Chris Mason (University College London) is internationally recognized to be at the forefront of the emerging field of stem cell and regenerative medicine translation and commercialization. A background in basic science, clinical medicine, bioprocessing and business has given Dr Mason a unique insight and understanding of the challenges facing the regen sector as it grows into a competitive and sustainable global healthcare industry.

Elisa Manzotti, Editorial Director of Future Medicine thanked the outgoing Senior Editor, "We owe profound thanks to Dr Minger. Under his wing, Regenerative Medicine has rapidly become the premier forum for the fast growing community of specialist stakeholders who address the complex challenge of translating and commercializing stem cell and regenerative medicine research into routine clinical practice."

Regenerative Medicine won the 2006 ALPSP/Charlesworth Award Best New Journal award from The Association of Learned and Professional Society Publishers. The journal is covered by the major abstracting and indexing databases, including MEDLINE, ISI Science Citation Index Expanded (SciSearch®), ISI Biotechnology Citation Index®, ISI Journal Citation Reports/Science, EMBASE and Scopus.

Dr Chris Mason said, "I have been involved with Regenerative Medicine since its inception and I am delighted to accept this senior appointment. We will continue to build our highly distinguished editorial team to support further growth of the journal, recognizing the need for both international representation and specializations. Although regenerative medicine and the associated regen industry is still, in many ways in its infancy, the coming years promise to yield major benefits to patients, healthcare providers and society. As ever increasing numbers of these novel regenerative medicine therapies move towards the clinic and into the market, Regenerative Medicine will provide the necessary all embracing expert coverage of these exciting translational advances."

Regenerative Medicine is published bimonthly in print and online formats and offers review articles, primary research, editorials, technology reports, interviews, perspectives and a variety of added-value content related to the translation and commercialization of stem cell and regenerative medicine research. The journal is aimed at all the regenerative medicine stakeholders and therefore covers a wide range of topics including scientific, clinical, commercial, legal and regulatory, as well as the political and ethical aspects. Rigorous peer review and rapid publication ensure that only the best quality and pertinent research is published in a timely manner. The electronic version of Regenerative Medicine is available from the Future Medicine website (www.futuremedicine.com) and from the Ingenta aggregation service (www.ingentaconnect.com).